Beyond blocking the GARP and latent TGF-β interaction on tumor cells, novel antibody-based strategies are emerging to block GARP/latent TGF-β complex on the surface of Tregs, thus preventing the secretion of active TGF-β. The gene discussed is LRRC32; the disease is neoplasm.